GAC & BDAZ - I had the same eye brow raising feeling GAC. As to whether the FDA excepts the trial data without US enrolment I would expect that as long as the FDA has approved the trial which they have, then it shouldn't matter where in the world the data came from, it's all real data. 

The really interesting point for me is that the cost of doing business should start to go down dramatically if the SSRA is positive. If my recollection is correct the highest recruiting numbers came in Apr, May, & Jun of 2016. As those patients pass the 120 week point there will be no more expense of carrying them.

The SSRA now seems to be the big enchilada as it will have the biggest effect on how many $$ will need to be raised be to complete the trial or whether another company would like to take it from there.

This was very good news this morning.

All IMO, dyodd

tada